HOME >> BIOLOGY >> NEWS
Although controversial, stem cell therapies exhibit potential in biotechnology markets

SAN ANTONIO June 11, 2002 Stem cells have enormous potential for repairing damage to the body caused by disease, injury, or aging. When introduced into an injured area of a patient, a stem cell could survive and repopulate the region with different types of cells, forming normal tissue.

Stem cells also offer the prospect of treating many inherited diseases caused
by a single, defective gene. Though other
treatments are available, such as gene therapy,
the longevity of benefits from stem cell treatment
provides a tantalizing option for researchers.

Heated controversy has arisen over the ethics of using embryonic stem cells, extracted from either very early embryos or fetuses. The United States has now limited stem cell use to a relatively small number of existing cell lines.

Stem cells are pluripotent, possessing the ability to differentiate into other types of cells. However, other stem cells, which are not derived from embryos and not completely pluripotent, have great potential to differentiate into cells, redeveloping certain tissues or organs. Hematopoietic cells, found in the bone marrow and umbilical cord, for example, can differentiate into all types of blood cells.

In order to make stem cell therapy a reality, it is not only necessary to have suitable stem cells, but also to know how to direct their differentiation and formation of new tissues. Scientists have begun to make new discoveries concerning genes and their protein products that govern various types of cell differentiation, but additional research is imperative.

Stem cell therapies are inherently more complicated than drug treatment, providing a stumbling block for stem cell therapy in the marketplace. However, while stem cell therapy remains costly, it will almost certainly last for several years before the procedure must be repeated. A low annual cost of $2500 per patient for stem cell therapy products at the manufacturers l
'"/>

Contact: Julia Rowell
jrowell@frost.com
210-247-3870
Technical Insights
12-Jun-2002


Page: 1 2

Related biology news :

1. UCI scientists successfully target key HIV protein; breakthrough may lead to new drug therapies
2. Serotonin metabolites in mollusks suggest pathways for human therapies
3. Columbia, Stony Brook, Guidant to develop biological pacemaker based on gene & cell therapies
4. Researchers identify two potential protein targets for new drug therapies for pancreatic cancer
5. Insight into transplant rejection might lead to novel prevention therapies
6. Scientists find second way to kill cancer cells: Discovery opens possibilities for new therapies
7. Insights on stroke from the peripheral blood suggest ways to develop markers and therapies
8. Novel approaches to current cellular therapies continue progress toward disease prevention
9. Novel therapies show promise against myeloid leukemia
10. Scientists discover potential approaches to enhance existing cancer therapies
11. Clock cells, tumor suicide, tailored therapies among subjects of AACR-NCI-EORTC Conference

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/1/2017)... , February 1, 2017 IDTechEx Research, ... on emerging technology, announces the availability of a new report, ... Continue Reading ... ... industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, ...
(Date:1/26/2017)... -- Acuity Market Intelligence today released the 2017 "Ten ... characterizes 2017 as a "breakout" year for biometrics ... new understanding of the potential benefits these technologies ... are often perceived as threats to privacy and ... Acuity Market intelligence. "However, taken together these technologies ...
(Date:1/23/2017)... DENVER , Jan. 23, 2017  The latest ... biometric smartphone prices have dropped dramatically. The quarterly average ... Q1 2013 to $276 in Q4 2016.  There are ... average price of $116, up from just 28 a ... According to Maxine Most , Acuity ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... , Feb. 16, 2017   Biostage, Inc. ... "Company"), a biotechnology company developing bioengineered organ implants to ... bronchus and trachea, announced today the closing on February ... 20,000,000 shares of common stock and warrants to purchase ... of $8.0 million. The offering was priced at $0.40 ...
(Date:2/16/2017)... ... February 16, 2017 , ... AxioMed announced ... professor and Harvard trained surgeon, completed the procedure on Monday, Jan. 30 at ... practicing female physician suffering from degenerative disc disease with radiculomyelopathy, as a result ...
(Date:2/15/2017)... ... February 15, 2017 , ... Executive search firm, Slone ... with GenePeeks. Matt is a veteran life sciences and molecular diagnostics executive ... focused on identifying inherited disease risk in future generations. In his new role, ...
(Date:2/15/2017)... , Feb. 15, 2017 Windtree Therapeutics, ... company focused on developing aerosolized KL4 surfactant therapies ... completed a $10.5 million private placement of convertible ... has sufficient capital to fund its operations through ... data release in mid-2017. Windtree has ...
Breaking Biology Technology:
Cached News: